Preclinical optimisation
A number of gene delivery systems have been evaluated in preclinical studies and a potentially optimal viral vector has been identified for EndoAngio-GT. Further preclinical development is required to optimise the product candidate for clinical trials.
|
 |
Market opportunity
There is substantial interest within the industry for novel anti-angiogenic approaches for the treatment of cancer. The market leader in the field, Avastin® (Genentech), generated sales in excess of US$4 billion in 2008. EndoAngio-GT could have competitive advantages in terms of safety and potency.
|
